Securities Daily, March 3 — When asked by researchers, Ruifeng High-tech stated that its controlling subsidiary, Ruifeng Yue Neng, is dedicated to the low-cost industrialization of black phosphorus products; its wholly owned subsidiary, Ruifeng Biological, mainly engages in the research and development and operation of synthetic biological materials. Currently, the dextran products have been sold in small batches, and production capacity is being expanded as appropriate; the company’s SBR battery binder has launched some product grades, and samples have been sent to multiple downstream customers for technical validation and integration, with ongoing efforts to improve product quality. The progress of these products and projects has been publicly disclosed. Although the company attaches great importance to them, most are in the incubation, initial, pilot, or technical validation stages. Future development and promotion still face significant uncertainties, and short-term revenue generated will be very limited, having little impact on performance.
(Editor: Wang Xue’er)
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Ruifeng High-tech: The holding subsidiary Ruifeng Yuenneng is committed to the low-cost industrialization of black phosphorus products
Securities Daily, March 3 — When asked by researchers, Ruifeng High-tech stated that its controlling subsidiary, Ruifeng Yue Neng, is dedicated to the low-cost industrialization of black phosphorus products; its wholly owned subsidiary, Ruifeng Biological, mainly engages in the research and development and operation of synthetic biological materials. Currently, the dextran products have been sold in small batches, and production capacity is being expanded as appropriate; the company’s SBR battery binder has launched some product grades, and samples have been sent to multiple downstream customers for technical validation and integration, with ongoing efforts to improve product quality. The progress of these products and projects has been publicly disclosed. Although the company attaches great importance to them, most are in the incubation, initial, pilot, or technical validation stages. Future development and promotion still face significant uncertainties, and short-term revenue generated will be very limited, having little impact on performance.
(Editor: Wang Xue’er)